Casdin Capital LLC grew its stake in shares of Standard BioTools Inc. (NASDAQ:LAB – Free Report) by 14.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,783,856 shares of the company’s stock after buying an additional 11,225,000 shares during the period. Standard BioTools accounts for about 7.1% of Casdin Capital LLC’s investment portfolio, making the stock its 4th largest position. Casdin Capital LLC owned about 0.23% of Standard BioTools worth $113,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Cibc World Markets Corp bought a new stake in shares of Standard BioTools during the fourth quarter valued at approximately $25,000. Aigen Investment Management LP bought a new stake in shares of Standard BioTools during the fourth quarter valued at approximately $28,000. M&T Bank Corp bought a new stake in shares of Standard BioTools during the fourth quarter valued at approximately $31,000. EntryPoint Capital LLC bought a new stake in shares of Standard BioTools during the fourth quarter valued at approximately $31,000. Finally, Russell Investments Group Ltd. raised its position in shares of Standard BioTools by 2,989.0% during the third quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after buying an additional 24,211 shares during the last quarter. Institutional investors own 53.74% of the company’s stock.
Standard BioTools Stock Performance
LAB stock opened at $0.81 on Thursday. The firm has a fifty day moving average price of $0.98 and a 200 day moving average price of $1.16. Standard BioTools Inc. has a fifty-two week low of $0.79 and a fifty-two week high of $1.72. The firm has a market cap of $316.24 million, a PE ratio of 4.05 and a beta of 1.39.
Wall Street Analyst Weigh In
Standard BioTools Profile
Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.
The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.
Featured Stories
- Five stocks we like better than Standard BioTools
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding LAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Standard BioTools Inc. (NASDAQ:LAB – Free Report).
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
